Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 9/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23140855 | 0.82 | CHRNB2 (0.38) | SCN9ACHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL23638876 | 0.78 | SCN9A (0.47) | SCN9ACHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL23639105 | 0.77 | SCN9A (0.49) | SCN9ACHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL25026228 | 0.77 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3HTR2A | |
| SCHEMBL23639020 | 0.76 | SCN9A (0.39) | SCN9ACHRNB2CHRNA4SLC6A4PNMT | |
| SCHEMBL23638945 | 0.74 | SCN9A (0.41) | SCN9A | |
| SCHEMBL23639107 | 0.73 | SCN9A (0.44) | SCN9A | |
| SCHEMBL25795120 | 0.70 | TRPV1 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3HTR2A | |
| SCHEMBL23140998 | 0.70 | SCN9A (0.45) | SCN9ACHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL20063500 | 0.70 | SCN9A (0.47) | SCN9AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214336-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214336-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | SCN1B, CACNA1A, SCN1A | SCN9A 34/4885CHRNB2 561/4885CHRNA4 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.